News & Events about Athersys Inc.
Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem (invimestrocel) for critical care indications, announced today it will host a business update conference call on February 14, 2023 at 11:00 a.m. Eastern Time. Dan Camardo, Chief Executive Officer...
Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem (invimestrocel) for critical care indications, announced today its participation in two upcoming conferences, the International Stroke Conference 2023 (ISC) from February 8-10, 2023 in Houston, TX...
Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem (invimestrocel) for critical care indications, announced today their participation in two January conferences, Advanced Therapies Week presented by Phacilitate from January 17-20, 2023 in Miami, FL and the 2nd...
Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem (invimestrocel) for critical care indications, today provided an update on ongoing clinical trials with MultiStem for the treatment of patients following hemorrhagic trauma (MATRICS-1) and for the treatment of...
Business Wire
2 months ago
Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem (invimestrocel) for critical care indications, announced today its participation in two November conferences, the Challenges and Opportunities for Mesenchymal Stem Cells digital conference being held November 17-18...